Post by i-Pharm GxP

On 2 April 2026, the FDA issued a warning letter that caught the Life Sciences industry's attention, and for good reason. Purolea Cosmetics Lab had used AI agents to generate drug specifications, SOPs, and master production records, and deployed them without adequate human review. When investigators asked why certain requirements hadn't been met, personnel allegedly said the AI hadn't told them they should. The FDA's response was clear, and it didn't need new rules to make it. In this month's GxP Insights, we examine what the Purolea warning letter means for AI in GxP manufacturing: → What happened and why it matters → The regulatory framework already in place → What responsible AI governance looks like in practice → The skills in growing demand --- Want more insights like this? ✅ Subscribe to GxP Insights for monthly deep dives into key topics across Medical Devices, Biologics, Cell & Gene Therapy, and Sterile/Aseptic Manufacturing ✅ Follow i-Pharm GxP for updates on life sciences regulation, talent demand, and market activity   #AI #GxP #Pharma #GMP #QA #Compliance #FDA #LifeSciences